Avacta Group PLC – AVCT – Rapid Antigen Test Detects SARS-CoV-2 Variants
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 rapid antigen lateral flow...
Read More